


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**  
**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sinobiopharm.com](http://www.sinobiopharm.com)*

**(Stock code: 1177)**

**VOLUNTARY ANNOUNCEMENT**  
**CATEGORY 1 INNOVATIVE DRUG “TQA3038 (siRNA)” COMPLETED**  
**PHASE I CLINICAL STUDY**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Phase I clinical study of the category 1 innovative drug “TQA3038 (siRNA)” self-developed by the Group has been successfully completed recently.

TQA3038 is a small interfering RNA (siRNA) drug self-developed by the Group that targets the hepatitis B virus (HBV), for the treatment of chronic hepatitis B. As a N-Acetylgalactosamine (GalNAc)-conjugated siRNA drug, TQA3038 can accumulate in the liver and effectively degrade the targeted RNA, inhibiting the translation of the relevant proteins and thereby blocking the replication of the HBV. It is expected to significantly improve the functional cure rate in clinical settings. TQA3038 utilizes nucleic acid sequences with independent intellectual property rights and exhibits stronger in vivo and in vitro antiviral activities compared with the siRNA that has made the fastest progress in clinical development.

A “randomized, doubleblind, placebo-controlled Phase I clinical trial for evaluating the safety, tolerability and pharmacokinetic characteristics of TQA3038 in healthy adult subjects” initiated by the Group has been successfully completed recently. The study was the first-in-human clinical trial of TQA3038 and all drug-related adverse incidents in the study belonged to Grades 1-2, with no serious adverse incidents.

The results of this study demonstrated that TQA3038 has a favourable safety and tolerability profile, similar to that of other similar siRNA drugs under investigation. The pharmacokinetic profile is consistent with its non-clinical pharmacokinetic features and is also similar to the human pharmacokinetic profile reported for other similar siRNA drugs under investigation. The Group will initiate subsequent clinical studies of TQA3038 Injection in patients with chronic hepatitis B in the near future.

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 25 April 2024

*As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.*